FEN1 inhibitor increases sensitivity of radiotherapy in cervical cancer cells

Background Cervical cancer is one of the most common causes of cancer‐associated mortality among affected women in the world. At present, treatment with weekly cisplatin plus ionizing radiation (IR) therapy is the standard regimen for cervical cancer, especially for locally advanced cervical cancer....

Full description

Saved in:
Bibliographic Details
Published inCancer medicine (Malden, MA) Vol. 8; no. 18; pp. 7774 - 7780
Main Authors Li, Jin‐Li, Wang, Jian‐Ping, Chang, Hong, Deng, Sheng‐Ming, Du, Jia‐Hui, Wang, Xiao‐Xiao, Hu, He‐Juan, Li, Dong‐Yin, Xu, Xiang‐Bin, Guo, Wei‐Qiang, Song, Yao‐Hua, Guo, Zhigang, Sun, Min‐Xuan, Wu, Yi‐Wei, Liu, Song‐Bai
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.12.2019
John Wiley and Sons Inc
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background Cervical cancer is one of the most common causes of cancer‐associated mortality among affected women in the world. At present, treatment with weekly cisplatin plus ionizing radiation (IR) therapy is the standard regimen for cervical cancer, especially for locally advanced cervical cancer. The purpose of this study is to determine whether FEN1 inhibitors could enhance the therapeutic effect of IR therapy. Methods Western blot was applied to determine the expression of FEN1‐ and apoptosis‐related proteins. Cell growth inhibition assay and colony formation assay were used to determine the effects of FEN1 inhibitor and IR exposure for Hela cells in vitro. CRISPR technology was used to knockdown FEN1 expression level of 293T cells, and tumor xenograft in nude mice was employed to determine the effects of FEN1 inhibitor and IR exposure on tumor growth in vivo. Results Our data revealed that FEN1 is overexpressed in HeLa cell and can be upregulated further by IR. We also demonstrated that FEN1 inhibitor enhances IR sensitivity of cervical cancer in vitro and in vivo. Conclusion FEN1 inhibitor SC13 could sensitize radiotherapy of cervical cancer cell. FEN1 is overexpressed in HeLa cell and the expression can be upregulated further by IR. FEN1 inhibitor enhances IR sensitivity of cervical cancer, and this enhancement effect was largely due to the impairment of DNA damage repair mechanism resulting from FEN1 inhibition, leading to apoptosis of cancer cells.
AbstractList BackgroundCervical cancer is one of the most common causes of cancer‐associated mortality among affected women in the world. At present, treatment with weekly cisplatin plus ionizing radiation (IR) therapy is the standard regimen for cervical cancer, especially for locally advanced cervical cancer. The purpose of this study is to determine whether FEN1 inhibitors could enhance the therapeutic effect of IR therapy.MethodsWestern blot was applied to determine the expression of FEN1‐ and apoptosis‐related proteins. Cell growth inhibition assay and colony formation assay were used to determine the effects of FEN1 inhibitor and IR exposure for Hela cells in vitro. CRISPR technology was used to knockdown FEN1 expression level of 293T cells, and tumor xenograft in nude mice was employed to determine the effects of FEN1 inhibitor and IR exposure on tumor growth in vivo.ResultsOur data revealed that FEN1 is overexpressed in HeLa cell and can be upregulated further by IR. We also demonstrated that FEN1 inhibitor enhances IR sensitivity of cervical cancer in vitro and in vivo.ConclusionFEN1 inhibitor SC13 could sensitize radiotherapy of cervical cancer cell.
Background Cervical cancer is one of the most common causes of cancer‐associated mortality among affected women in the world. At present, treatment with weekly cisplatin plus ionizing radiation (IR) therapy is the standard regimen for cervical cancer, especially for locally advanced cervical cancer. The purpose of this study is to determine whether FEN1 inhibitors could enhance the therapeutic effect of IR therapy. Methods Western blot was applied to determine the expression of FEN1‐ and apoptosis‐related proteins. Cell growth inhibition assay and colony formation assay were used to determine the effects of FEN1 inhibitor and IR exposure for Hela cells in vitro. CRISPR technology was used to knockdown FEN1 expression level of 293T cells, and tumor xenograft in nude mice was employed to determine the effects of FEN1 inhibitor and IR exposure on tumor growth in vivo. Results Our data revealed that FEN1 is overexpressed in HeLa cell and can be upregulated further by IR. We also demonstrated that FEN1 inhibitor enhances IR sensitivity of cervical cancer in vitro and in vivo. Conclusion FEN1 inhibitor SC13 could sensitize radiotherapy of cervical cancer cell. FEN1 is overexpressed in HeLa cell and the expression can be upregulated further by IR. FEN1 inhibitor enhances IR sensitivity of cervical cancer, and this enhancement effect was largely due to the impairment of DNA damage repair mechanism resulting from FEN1 inhibition, leading to apoptosis of cancer cells.
Abstract Background Cervical cancer is one of the most common causes of cancer‐associated mortality among affected women in the world. At present, treatment with weekly cisplatin plus ionizing radiation (IR) therapy is the standard regimen for cervical cancer, especially for locally advanced cervical cancer. The purpose of this study is to determine whether FEN1 inhibitors could enhance the therapeutic effect of IR therapy. Methods Western blot was applied to determine the expression of FEN1‐ and apoptosis‐related proteins. Cell growth inhibition assay and colony formation assay were used to determine the effects of FEN1 inhibitor and IR exposure for Hela cells in vitro. CRISPR technology was used to knockdown FEN1 expression level of 293T cells, and tumor xenograft in nude mice was employed to determine the effects of FEN1 inhibitor and IR exposure on tumor growth in vivo. Results Our data revealed that FEN1 is overexpressed in HeLa cell and can be upregulated further by IR. We also demonstrated that FEN1 inhibitor enhances IR sensitivity of cervical cancer in vitro and in vivo. Conclusion FEN1 inhibitor SC13 could sensitize radiotherapy of cervical cancer cell.
Cervical cancer is one of the most common causes of cancer-associated mortality among affected women in the world. At present, treatment with weekly cisplatin plus ionizing radiation (IR) therapy is the standard regimen for cervical cancer, especially for locally advanced cervical cancer. The purpose of this study is to determine whether FEN1 inhibitors could enhance the therapeutic effect of IR therapy. Western blot was applied to determine the expression of FEN1- and apoptosis-related proteins. Cell growth inhibition assay and colony formation assay were used to determine the effects of FEN1 inhibitor and IR exposure for Hela cells in vitro. CRISPR technology was used to knockdown FEN1 expression level of 293T cells, and tumor xenograft in nude mice was employed to determine the effects of FEN1 inhibitor and IR exposure on tumor growth in vivo. Our data revealed that FEN1 is overexpressed in HeLa cell and can be upregulated further by IR. We also demonstrated that FEN1 inhibitor enhances IR sensitivity of cervical cancer in vitro and in vivo. FEN1 inhibitor SC13 could sensitize radiotherapy of cervical cancer cell.
Abstract Background Cervical cancer is one of the most common causes of cancer‐associated mortality among affected women in the world. At present, treatment with weekly cisplatin plus ionizing radiation (IR) therapy is the standard regimen for cervical cancer, especially for locally advanced cervical cancer. The purpose of this study is to determine whether FEN1 inhibitors could enhance the therapeutic effect of IR therapy. Methods Western blot was applied to determine the expression of FEN1‐ and apoptosis‐related proteins. Cell growth inhibition assay and colony formation assay were used to determine the effects of FEN1 inhibitor and IR exposure for Hela cells in vitro. CRISPR technology was used to knockdown FEN1 expression level of 293T cells, and tumor xenograft in nude mice was employed to determine the effects of FEN1 inhibitor and IR exposure on tumor growth in vivo. Results Our data revealed that FEN1 is overexpressed in HeLa cell and can be upregulated further by IR. We also demonstrated that FEN1 inhibitor enhances IR sensitivity of cervical cancer in vitro and in vivo. Conclusion FEN1 inhibitor SC13 could sensitize radiotherapy of cervical cancer cell.
FEN1 is overexpressed in HeLa cell and the expression can be upregulated further by IR. FEN1 inhibitor enhances IR sensitivity of cervical cancer, and this enhancement effect was largely due to the impairment of DNA damage repair mechanism resulting from FEN1 inhibition, leading to apoptosis of cancer cells.
Author Liu, Song‐Bai
Xu, Xiang‐Bin
Deng, Sheng‐Ming
Guo, Wei‐Qiang
Hu, He‐Juan
Li, Dong‐Yin
Wang, Jian‐Ping
Chang, Hong
Guo, Zhigang
Du, Jia‐Hui
Wang, Xiao‐Xiao
Li, Jin‐Li
Song, Yao‐Hua
Sun, Min‐Xuan
Wu, Yi‐Wei
AuthorAffiliation 6 Cyrus Tang Hematology Center Collaborative Innovation Center of Hematology Soochow University Suzhou China
7 Jiangsu Key Laboratory for Molecular and Medical Biotechnology College of Life Science Nanjing Normal University Nanjing China
3 Department of Nuclear Medicine The Affiliated Hospital of Soochow University Suzhou China
1 Department of Radiation Oncology The Affiliated Hospital of Soochow University Suzhou China
8 Jiangsu Key Laboratory of Medical Optics Suzhou Institute of Biomedical Engineering and Technology Chinese Academy of Sciences Suzhou China
2 Suzhou Key Laboratory for Medical Biotechnology Suzhou Vocational Health College Suzhou China
4 College of Food Science and Technology Hainan University Haikou China
5 School of Chemistry, Biology and Materials Engineering Suzhou University of Science and Technology Suzhou China
AuthorAffiliation_xml – name: 7 Jiangsu Key Laboratory for Molecular and Medical Biotechnology College of Life Science Nanjing Normal University Nanjing China
– name: 8 Jiangsu Key Laboratory of Medical Optics Suzhou Institute of Biomedical Engineering and Technology Chinese Academy of Sciences Suzhou China
– name: 2 Suzhou Key Laboratory for Medical Biotechnology Suzhou Vocational Health College Suzhou China
– name: 4 College of Food Science and Technology Hainan University Haikou China
– name: 6 Cyrus Tang Hematology Center Collaborative Innovation Center of Hematology Soochow University Suzhou China
– name: 1 Department of Radiation Oncology The Affiliated Hospital of Soochow University Suzhou China
– name: 3 Department of Nuclear Medicine The Affiliated Hospital of Soochow University Suzhou China
– name: 5 School of Chemistry, Biology and Materials Engineering Suzhou University of Science and Technology Suzhou China
Author_xml – sequence: 1
  givenname: Jin‐Li
  surname: Li
  fullname: Li, Jin‐Li
  organization: The Affiliated Hospital of Soochow University
– sequence: 2
  givenname: Jian‐Ping
  surname: Wang
  fullname: Wang, Jian‐Ping
  organization: The Affiliated Hospital of Soochow University
– sequence: 3
  givenname: Hong
  surname: Chang
  fullname: Chang, Hong
  organization: Suzhou Vocational Health College
– sequence: 4
  givenname: Sheng‐Ming
  surname: Deng
  fullname: Deng, Sheng‐Ming
  organization: The Affiliated Hospital of Soochow University
– sequence: 5
  givenname: Jia‐Hui
  surname: Du
  fullname: Du, Jia‐Hui
  organization: Suzhou Vocational Health College
– sequence: 6
  givenname: Xiao‐Xiao
  surname: Wang
  fullname: Wang, Xiao‐Xiao
  organization: Suzhou Vocational Health College
– sequence: 7
  givenname: He‐Juan
  surname: Hu
  fullname: Hu, He‐Juan
  organization: Suzhou Vocational Health College
– sequence: 8
  givenname: Dong‐Yin
  surname: Li
  fullname: Li, Dong‐Yin
  organization: Suzhou Vocational Health College
– sequence: 9
  givenname: Xiang‐Bin
  surname: Xu
  fullname: Xu, Xiang‐Bin
  organization: Hainan University
– sequence: 10
  givenname: Wei‐Qiang
  surname: Guo
  fullname: Guo, Wei‐Qiang
  organization: Suzhou University of Science and Technology
– sequence: 11
  givenname: Yao‐Hua
  surname: Song
  fullname: Song, Yao‐Hua
  organization: Soochow University
– sequence: 12
  givenname: Zhigang
  surname: Guo
  fullname: Guo, Zhigang
  organization: Nanjing Normal University
– sequence: 13
  givenname: Min‐Xuan
  surname: Sun
  fullname: Sun, Min‐Xuan
  email: sunmx@sibet.ac.cn
  organization: Chinese Academy of Sciences
– sequence: 14
  givenname: Yi‐Wei
  surname: Wu
  fullname: Wu, Yi‐Wei
  email: wuyiwei3988@gmail.com
  organization: The Affiliated Hospital of Soochow University
– sequence: 15
  givenname: Song‐Bai
  orcidid: 0000-0002-3920-1032
  surname: Liu
  fullname: Liu, Song‐Bai
  email: liusongbai@126.com
  organization: Suzhou Vocational Health College
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31670906$$D View this record in MEDLINE/PubMed
BookMark eNp1kcFOGzEQhi1EVSjlwAtUK_XEIWDP2t7spRKKoEWC9tKerdnZWeJos07tTVDeHodQBIf64rH96Rvb_ydxOISBhThT8kJJCZeES30BVpkDcQxSm0llS334pj4SpyktZB6VBFupj-KoVLaStbTH4v7m-qcq_DD3jR9DzBVFxsSpSDwkP_qNH7dF6IqIrQ_jnCOutpkqiOPGE_YF4ZDrvO779Fl86LBPfPoyn4g_N9e_Zz8md7--386u7iZkZG0mRhMZU0szBQbQCBU0rUSjoFWm0XXVkTZNxYwSZAeqtVONHZZk67Ykw-WJuN1724ALt4p-iXHrAnr3vBHig8M4eurZtbYxNTHZpiy1tbZp6oqkssYAAQJk17e9a7VultwSD2PE_p30_cng5-4hbJytFUg7zYKvL4IY_q45jW4R1nHI73dQ5g832oDK1PmeohhSity9dlDS7YJ0uyDdLsjMfnl7pVfyX2wZuNwDj77n7f9NbnZ1r5-VT8fOqKY
CitedBy_id crossref_primary_10_1021_acs_analchem_0c05275
crossref_primary_10_1016_j_aca_2023_341275
crossref_primary_10_1016_j_ecoenv_2024_116537
crossref_primary_10_1021_acs_analchem_3c00930
crossref_primary_10_1016_j_saa_2022_122295
crossref_primary_10_1021_acssynbio_2c00420
crossref_primary_10_1089_gtmb_2023_0024
crossref_primary_10_2139_ssrn_4135365
crossref_primary_10_12677_ACM_2023_132267
crossref_primary_10_35118_apjmbb_2020_028_3_09
crossref_primary_10_1016_j_snb_2024_135986
crossref_primary_10_1016_j_pbiomolbio_2020_10_005
crossref_primary_10_2139_ssrn_4092896
crossref_primary_10_3390_ijms25042110
crossref_primary_10_1186_s12885_021_08101_2
crossref_primary_10_1016_j_aca_2020_12_069
crossref_primary_10_1021_acs_analchem_1c00829
crossref_primary_10_1016_j_aca_2024_342395
crossref_primary_10_1038_s41434_020_00215_9
crossref_primary_10_1016_j_biopha_2022_113345
crossref_primary_10_1186_s12906_020_02983_8
crossref_primary_10_3390_biom12071007
crossref_primary_10_1007_s12598_021_01885_z
crossref_primary_10_1016_j_dld_2023_08_050
crossref_primary_10_1016_j_aca_2022_340519
crossref_primary_10_1038_s41419_020_02812_3
Cites_doi 10.1056/NEJM199904153401503
10.1186/s12967-015-0689-4
10.1002/bies.20255
10.1091/mbc.e15-05-0260
10.1088/0031-9155/60/11/4551
10.1073/pnas.1614430113
10.1016/j.molonc.2014.04.009
10.3322/caac.21338
10.1016/j.ygyno.2014.04.049
10.1002/1878-0261.12118
10.15252/embj.201489865
10.1016/j.dnarep.2018.01.003
10.1186/s40779-018-0167-4
10.1002/bies.950190309
10.3390/biom5043204
10.1016/j.ebiom.2016.11.012
10.3322/caac.21262
10.1146/annurev-physchem-040513-103605
10.1016/S0021-9258(17)42175-2
10.1056/NEJM199904153401502
10.1016/S1470-2045(00)00391-0
10.1038/ng.3173
10.1126/science.4048939
10.1021/acs.jpcb.5b03948
10.4061/2010/182894
10.1146/annurev-biochem-072511-122603
10.3892/ijmm.2014.1682
10.1093/nar/gkq884
10.18632/oncotarget.24109
10.1016/j.ygyno.2018.07.005
10.1186/s12885-015-1043-1
ContentType Journal Article
Copyright 2019 The Authors. published by John Wiley & Sons Ltd.
2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2019 The Authors. published by John Wiley & Sons Ltd.
– notice: 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
– notice: 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
WIN
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7X7
7XB
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M7P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
5PM
DOA
DOI 10.1002/cam4.2615
DatabaseName Wiley-Blackwell Open Access Collection
Wiley Online Library Free Content
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
ProQuest Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
Biological Science Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest Central (Alumni)
DatabaseTitleList Publicly Available Content Database

CrossRef
MEDLINE


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 24P
  name: Wiley-Blackwell Open Access Collection
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate LI et al
EISSN 2045-7634
EndPage 7780
ExternalDocumentID oai_doaj_org_article_d6b59cec6b334666bb97c016552c2a22
10_1002_cam4_2615
31670906
CAM42615
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: Natural Science Foundation of Jiangsu Province of China
  funderid: BK20170386; BK20160348
– fundername: Natural Science Foundation of the Jiangsu Higher Education Institutions of China
  funderid: 17KJB180013
– fundername: Applied Basic Research Project of Suzhou City
  funderid: SYS2019037; SYSD2017061
– fundername: Qing‐Lan Project of Jiangsu Province in China
– fundername: Key Programs of the Suzhou Vocational Health College
  funderid: szwzy201708
– fundername: Science and Technology Project for the Youth of Suzhou
– fundername: Science and Technology Innovation Team Project of the Suzhou Vocational Health College
  funderid: kjxw2015004; SZWZYTD201804
– fundername: National Natural Science Foundation of China
  funderid: 31701198; 81601522
– fundername: Jiangsu Provincial Medical Youth Talent Program
  funderid: QNRC2016771; QNRC2016749
– fundername: Science and Technology Innovation Team Project of the Suzhou Vocational Health College
  grantid: kjxw2015004
– fundername: Science and Technology Innovation Team Project of the Suzhou Vocational Health College
  grantid: SZWZYTD201804
– fundername: Natural Science Foundation of the Jiangsu Higher Education Institutions of China
  grantid: 17KJB180013
– fundername: National Natural Science Foundation of China
  grantid: 31701198
– fundername: Natural Science Foundation of Jiangsu Province of China
  grantid: BK20160348
– fundername: Qing-Lan Project of Jiangsu Province in China
– fundername: Applied Basic Research Project of Suzhou City
  grantid: SYSD2017061
– fundername: Jiangsu Provincial Medical Youth Talent Program
  grantid: QNRC2016771
– fundername: National Natural Science Foundation of China
  grantid: 81601522
– fundername: ;
  grantid: 31701198; 81601522
– fundername: Jiangsu Provincial Medical Youth Talent Program
  grantid: QNRC2016771; QNRC2016749
– fundername: Applied Basic Research Project of Suzhou City
  grantid: SYS2019037; SYSD2017061
– fundername: Science and Technology Innovation Team Project of the Suzhou Vocational Health College
  grantid: kjxw2015004; SZWZYTD201804
– fundername: Key Programs of the Suzhou Vocational Health College
  grantid: szwzy201708
– fundername: ;
  grantid: BK20170386; BK20160348
GroupedDBID 0R~
1OC
24P
31~
53G
5VS
7X7
8-0
8-1
8FE
8FH
8FI
8FJ
AAHHS
AAZKR
ABDBF
ABUWG
ACCFJ
ACXQS
ADBBV
ADKYN
ADRAZ
ADZMN
ADZOD
AEEZP
AENEX
AEQDE
AFKRA
AIWBW
AJBDE
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AOIJS
AVUZU
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
CCPQU
D-8
D-9
DIK
EBS
EJD
FYUFA
GODZA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
HZ~
IAO
IHR
KQ8
LK8
M48
M7P
M~E
O9-
OK1
OVD
PIMPY
PQQKQ
PROAC
RPM
TEORI
TUS
UKHRP
WIN
CGR
CUY
CVF
ECM
EIF
ITC
NPM
AAYXX
CITATION
3V.
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PQEST
PQUKI
PRINS
5PM
ID FETCH-LOGICAL-c5095-54cc5590582e224a272bd0a512d15b497fc45b7eea020f21d684afa3c69d3c5e3
IEDL.DBID RPM
ISSN 2045-7634
IngestDate Thu Jul 04 21:06:16 EDT 2024
Tue Sep 17 21:19:06 EDT 2024
Tue Sep 24 21:57:25 EDT 2024
Thu Sep 26 19:09:34 EDT 2024
Sat Sep 28 08:25:38 EDT 2024
Sat Aug 24 01:09:08 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 18
Keywords radiotherapy
targeted therapy
FEN1
cervical cancer
Language English
License Attribution
2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5095-54cc5590582e224a272bd0a512d15b497fc45b7eea020f21d684afa3c69d3c5e3
Notes Jin‐Li Li, Jian‐Ping Wang, Hong Chang and Sheng‐Ming Deng contributed equally to this work and as the first author.
ORCID 0000-0002-3920-1032
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912068/
PMID 31670906
PQID 2326754521
PQPubID 2032540
PageCount 7
ParticipantIDs doaj_primary_oai_doaj_org_article_d6b59cec6b334666bb97c016552c2a22
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6912068
proquest_journals_2326754521
crossref_primary_10_1002_cam4_2615
pubmed_primary_31670906
wiley_primary_10_1002_cam4_2615_CAM42615
PublicationCentury 2000
PublicationDate December 2019
PublicationDateYYYYMMDD 2019-12-01
PublicationDate_xml – month: 12
  year: 2019
  text: December 2019
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Bognor Regis
– name: Hoboken
PublicationTitle Cancer medicine (Malden, MA)
PublicationTitleAlternate Cancer Med
PublicationYear 2019
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
– name: Wiley
References 2015; 13
2015; 34
2015; 15
2015; 5
2010; 2010
1999; 340
2018; 63
2011; 39
2005; 27
2016; 14
2014; 134
2018; 9
2015; 47
2018; 5
1994; 269
2018; 150
2015; 60
2017; 11
2015; 66
2015; 65
2016; 113
1997; 19
2013; 82
2015; 119
2001; 2
2014; 8
2016; 27
1985; 230
2014; 33
2016; 66
e_1_2_8_28_1
e_1_2_8_29_1
e_1_2_8_24_1
e_1_2_8_25_1
e_1_2_8_26_1
e_1_2_8_27_1
e_1_2_8_3_1
e_1_2_8_2_1
e_1_2_8_5_1
e_1_2_8_4_1
e_1_2_8_7_1
e_1_2_8_6_1
e_1_2_8_9_1
e_1_2_8_8_1
e_1_2_8_20_1
e_1_2_8_21_1
e_1_2_8_22_1
e_1_2_8_23_1
e_1_2_8_17_1
e_1_2_8_18_1
e_1_2_8_19_1
e_1_2_8_13_1
e_1_2_8_14_1
e_1_2_8_15_1
e_1_2_8_16_1
e_1_2_8_32_1
e_1_2_8_10_1
e_1_2_8_31_1
e_1_2_8_11_1
e_1_2_8_12_1
e_1_2_8_30_1
References_xml – volume: 269
  start-page: 787
  issue: 2
  year: 1994
  end-page: 790
  article-title: Cellular responses to cisplatin. The roles of DNA‐binding proteins and DNA repair
  publication-title: J Biol Chem
– volume: 13
  start-page: 328
  year: 2015
  article-title: Bcl‐2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose‐dependent toxicity and resistance
  publication-title: J Transl Med
– volume: 134
  start-page: 166
  issue: 1
  year: 2014
  end-page: 171
  article-title: Radiotherapy with concurrent cisplatin‐based doublet or weekly cisplatin for cervical cancer: a systematic review and meta‐analysis
  publication-title: Gynecol Oncol
– volume: 11
  start-page: 1302
  issue: 9
  year: 2017
  end-page: 1303
  article-title: FEN1 promotes tumor progression and confers cisplatin resistance in non‐small‐cell lung cancer
  publication-title: Molecular oncology
– volume: 19
  start-page: 233
  issue: 3
  year: 1997
  end-page: 240
  article-title: The FEN‐1 family of structure‐specific nucleases in eukaryotic DNA replication, recombination and repair
  publication-title: BioEssays
– volume: 340
  start-page: 1154
  issue: 15
  year: 1999
  end-page: 1161
  article-title: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma
  publication-title: N Engl J Med
– volume: 34
  start-page: 1829
  issue: 13
  year: 2015
  end-page: 1843
  article-title: Okazaki fragment maturation involves alpha‐segment error editing by the mammalian FEN1/MutSalpha functional complex
  publication-title: EMBO J
– volume: 150
  start-page: 412
  issue: 3
  year: 2018
  end-page: 419
  article-title: The efficacy of concurrent weekly carboplatin with radiotherapy in the treatment of cervical cancer: a meta‐analysis
  publication-title: Gynecol Oncol
– volume: 60
  start-page: 4551
  issue: 11
  year: 2015
  end-page: 4564
  article-title: Cellular signalling effects in high precision radiotherapy
  publication-title: Phys Med Biol
– volume: 47
  start-page: 115
  issue: 2
  year: 2015
  end-page: 125
  article-title: Gene expression analysis identifies global gene dosage sensitivity in cancer
  publication-title: Nat Genet
– volume: 8
  start-page: 1326
  issue: 7
  year: 2014
  end-page: 1338
  article-title: Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer
  publication-title: Molecular oncology
– volume: 9
  start-page: 11268
  issue: 13
  year: 2018
  end-page: 11278
  article-title: Curcumin increases breast cancer cell sensitivity to cisplatin by decreasing FEN1 expression
  publication-title: Oncotarget
– volume: 2010
  start-page: 1
  year: 2010
  end-page: 16
  article-title: Cellular responses to Cisplatin‐induced DNA damage
  publication-title: J Nucleic Acids
– volume: 340
  start-page: 1144
  issue: 15
  year: 1999
  end-page: 1153
  article-title: Concurrent cisplatin‐based radiotherapy and chemotherapy for locally advanced cervical cancer
  publication-title: N Engl J Med
– volume: 82
  start-page: 119
  year: 2013
  end-page: 138
  article-title: Flap endonuclease 1
  publication-title: Annu Rev Biochem
– volume: 33
  start-page: 1268
  issue: 5
  year: 2014
  end-page: 1274
  article-title: Flap endonuclease 1 is a promising candidate biomarker in gastric cancer and is involved in cell proliferation and apoptosis
  publication-title: Int J Mol Med
– volume: 230
  start-page: 412
  issue: 4724
  year: 1985
  end-page: 417
  article-title: X‐ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis‐[Pt(NH3)2(d(pGpG))]
  publication-title: Science
– volume: 66
  start-page: 379
  year: 2015
  end-page: 398
  article-title: Biomolecular damage induced by ionizing radiation: the direct and indirect effects of low‐energy electrons on DNA
  publication-title: Annu Rev Phys Chem
– volume: 14
  start-page: 32
  year: 2016
  end-page: 43
  article-title: Targeting DNA flap endonuclease 1 to impede breast cancer progression
  publication-title: EBioMedicine
– volume: 113
  start-page: 11507
  issue: 41
  year: 2016
  end-page: 11512
  article-title: Cisplatin DNA damage and repair maps of the human genome at single‐nucleotide resolution
  publication-title: Proc Natl Acad Sci USA
– volume: 5
  start-page: 20
  issue: 1
  year: 2018
  article-title: Biological effects of radiation on cancer cells
  publication-title: Mil Med Res
– volume: 39
  start-page: 781
  issue: 3
  year: 2011
  end-page: 794
  article-title: Functional regulation of FEN1 nuclease and its link to cancer
  publication-title: Nucleic Acids Res
– volume: 15
  start-page: 50
  year: 2015
  article-title: YY1 suppresses FEN1 over‐expression and drug resistance in breast cancer
  publication-title: BMC Cancer
– volume: 119
  start-page: 8227
  issue: 26
  year: 2015
  end-page: 8238
  article-title: Mechanisms of damage to DNA labeled with electrophilic nucleobases induced by ionizing or UV radiation
  publication-title: J Phys Chem B
– volume: 66
  start-page: 115
  issue: 2
  year: 2016
  end-page: 132
  article-title: Cancer statistics in China, 2015
  publication-title: CA Cancer J Clin
– volume: 5
  start-page: 3204
  issue: 4
  year: 2015
  end-page: 3259
  article-title: DNA damage signalling and repair inhibitors: the long‐sought‐after Achilles' heel of cancer
  publication-title: Biomolecules
– volume: 65
  start-page: 87
  issue: 2
  year: 2015
  end-page: 108
  article-title: Global cancer statistics, 2012
  publication-title: CA Cancer J Clin
– volume: 2
  start-page: 366
  issue: 6
  year: 2001
  end-page: 370
  article-title: Radiotherapy and cellular signalling
  publication-title: Lancet Oncol
– volume: 27
  start-page: 717
  issue: 7
  year: 2005
  end-page: 729
  article-title: Multiple but dissectible functions of FEN‐1 nucleases in nucleic acid processing, genome stability and diseases
  publication-title: BioEssays
– volume: 63
  start-page: 1
  year: 2018
  end-page: 9
  article-title: Synergistic antitumor effect of combined paclitaxel with FEN1 inhibitor in cervical cancer cells
  publication-title: DNA Repair (Amst)
– volume: 27
  start-page: 223
  issue: 2
  year: 2016
  end-page: 235
  article-title: Microhomology‐mediated end joining is the principal mediator of double‐strand break repair during mitochondrial DNA lesions
  publication-title: Mol Biol Cell
– ident: e_1_2_8_17_1
  doi: 10.1056/NEJM199904153401503
– ident: e_1_2_8_18_1
  doi: 10.1186/s12967-015-0689-4
– ident: e_1_2_8_22_1
  doi: 10.1002/bies.20255
– ident: e_1_2_8_32_1
  doi: 10.1091/mbc.e15-05-0260
– ident: e_1_2_8_9_1
  doi: 10.1088/0031-9155/60/11/4551
– ident: e_1_2_8_11_1
  doi: 10.1073/pnas.1614430113
– ident: e_1_2_8_29_1
  doi: 10.1016/j.molonc.2014.04.009
– ident: e_1_2_8_2_1
  doi: 10.3322/caac.21338
– ident: e_1_2_8_4_1
  doi: 10.1016/j.ygyno.2014.04.049
– ident: e_1_2_8_19_1
  doi: 10.1002/1878-0261.12118
– ident: e_1_2_8_23_1
  doi: 10.15252/embj.201489865
– ident: e_1_2_8_24_1
  doi: 10.1016/j.dnarep.2018.01.003
– ident: e_1_2_8_5_1
  doi: 10.1186/s40779-018-0167-4
– ident: e_1_2_8_30_1
  doi: 10.1002/bies.950190309
– ident: e_1_2_8_8_1
  doi: 10.3390/biom5043204
– ident: e_1_2_8_25_1
  doi: 10.1016/j.ebiom.2016.11.012
– ident: e_1_2_8_3_1
  doi: 10.3322/caac.21262
– ident: e_1_2_8_6_1
  doi: 10.1146/annurev-physchem-040513-103605
– ident: e_1_2_8_13_1
  doi: 10.1016/S0021-9258(17)42175-2
– ident: e_1_2_8_16_1
  doi: 10.1056/NEJM199904153401502
– ident: e_1_2_8_10_1
  doi: 10.1016/S1470-2045(00)00391-0
– ident: e_1_2_8_31_1
  doi: 10.1038/ng.3173
– ident: e_1_2_8_12_1
  doi: 10.1126/science.4048939
– ident: e_1_2_8_7_1
  doi: 10.1021/acs.jpcb.5b03948
– ident: e_1_2_8_14_1
  doi: 10.4061/2010/182894
– ident: e_1_2_8_20_1
  doi: 10.1146/annurev-biochem-072511-122603
– ident: e_1_2_8_28_1
  doi: 10.3892/ijmm.2014.1682
– ident: e_1_2_8_21_1
  doi: 10.1093/nar/gkq884
– ident: e_1_2_8_26_1
  doi: 10.18632/oncotarget.24109
– ident: e_1_2_8_15_1
  doi: 10.1016/j.ygyno.2018.07.005
– ident: e_1_2_8_27_1
  doi: 10.1186/s12885-015-1043-1
SSID ssj0000702671
Score 2.3420746
Snippet Background Cervical cancer is one of the most common causes of cancer‐associated mortality among affected women in the world. At present, treatment with weekly...
Cervical cancer is one of the most common causes of cancer-associated mortality among affected women in the world. At present, treatment with weekly cisplatin...
Abstract Background Cervical cancer is one of the most common causes of cancer‐associated mortality among affected women in the world. At present, treatment...
BackgroundCervical cancer is one of the most common causes of cancer‐associated mortality among affected women in the world. At present, treatment with weekly...
FEN1 is overexpressed in HeLa cell and the expression can be upregulated further by IR. FEN1 inhibitor enhances IR sensitivity of cervical cancer, and this...
Abstract Background Cervical cancer is one of the most common causes of cancer‐associated mortality among affected women in the world. At present, treatment...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
wiley
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 7774
SubjectTerms Animals
Apoptosis
Apoptosis - drug effects
Apoptosis - radiation effects
Cancer Biology
Cancer therapies
Cell Line, Tumor
Cell Survival - drug effects
Cell Survival - radiation effects
Cervical cancer
Cervix
Cisplatin
CRISPR
Deoxyribonucleic acid
Disease Models, Animal
DNA
DNA damage
DNA repair
Enzyme Inhibitors - pharmacology
Female
FEN1
FEN1 protein
Flap Endonucleases - antagonists & inhibitors
Flap Endonucleases - genetics
Flap Endonucleases - metabolism
Gene Expression
Gene Expression Regulation, Neoplastic - drug effects
Gene Expression Regulation, Neoplastic - radiation effects
Grants
Growth inhibition
HeLa Cells
Humans
Immunoglobulins
Ionizing radiation
Lung cancer
Mice
Original Research
Proteins
Radiation therapy
Radiation Tolerance - drug effects
Radiation, Ionizing
Radiation-Sensitizing Agents - pharmacology
radiotherapy
Science
targeted therapy
Uterine Cervical Neoplasms - genetics
Uterine Cervical Neoplasms - metabolism
Uterine Cervical Neoplasms - pathology
Xenograft Model Antitumor Assays
Xenografts
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07T8MwED4hBsSCeBNeihADSyBx7LgeoWqFkMoEUjfLr4gMpKgpA_-ec5yiRoBY2KLESew7x_d98T0ALomyAyuoSjLO84QS5KzCaVwMtcut4gpRrN_RnTwW98_0YcqmK6W-vE9YSA8cBHdjC82EcabQeU4Ra2stuPExOIwYokhYfTO2QqbaNZj7ykrZMpVQSm6MeqXXSBdYzwC1efp_ApfffSRXsWtrfMbbsNWhxvg29HYH1ly9CxuTbl98Dybj0WMWV_VLpfELneORB4ONa-LGO6iHChHxrIznylZdzNUHtopNu1Tgo43X_jz2__GbfXgej56G90lXKCExaO9ZwqgxyAxSNiAOTbIinGibKrTlNmOaCl4ayjR3TiE4LElmiwFVpcpNIWxumMsPYL2e1e4IYmTE1sfrIpAqaemsckRThSxQ4Y1UpBFcLKUn30I-DBkyHxPpRSy9iCO483L9auBTWLcnULGyU6z8S7ERnC61IrvvqpGI_5DhUMQcERwGBX29xcf0pyItIuA91fW60b9SVy9tRu1CZDhLBxFctUr-fWRyeDvxpJMd_8cQT2AT8ZcI3jGnsL6Yv7szxDgLfd5O508i4fgz
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB5RkKpeELS0DS9FFQcu6SaOnaxPCNCuVpV2VaEicbP8StkDWZosB_49M3ksrArcosRxnJmx5xvPwwAnTLuhk1xHSZ6nEWdos0pvcDE0PnU614hiyaM7nWWTa_7rRtxswKTPhaGwyn5NbBZqt7C0Rz5AzY_YlqO2GWhDuwB2OTi7_xfR-VHkZ-0O0_gAWyzh5LDduhjNfl-t9ltQtLGDpC8uFLOB1Xf8JxoQYk0lNZX7X4Ob_0dNvkSzjToa78B2hyPD85bxu7Dhy8_wcdp5yr_AdDyaJeG8vJ0bnLMVXhE8rH0d1hSy3p4ZES6KsNJu3mVhPWKr0DaLB3ZtSR6qkHb26z24Ho_-XE6i7uiEyCICEJHg1qKtEIsh86ikNcuZcbFG7e4SYbjMC8uFyb3XCBcLlrhsyHWhU5tJl1rh06-wWS5K_x1CtJEdZfAitCp44Z32zHCNdqHGF7mMA_jRU0_dtxUyVFsLmSkisSISB3BBdF01oKLWzY1F9Vd1c0S5zAhpvc1MmnI0q4yRuaV0K8Es04wFcNhzRXUzrVbPchHAt5ZBq69Qln8s4yyAfI11a8NYf1LOb5sa25lMUG6HAZw2TH77z9Tl-ZTMULH__ugO4BNiLdlGwhzC5rJ68EeIZ5bmuBPVJ5z59Rk
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access(OpenAccess)
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwEB5RkFAviLa0pGyrCPXAJTRx_FgfEFoQK4QUTqzEzfIrZSXItskilX_POA_ECrhxixLn4Zmx5_tizwzAL6Ld2Emqk0yIPKEEOav0BidD43OnhUYUG1Z0i0t-PqMX1-x6DYYam70Am1epXagnNatvD___ezjGAX_UJxD9bfUdPUQmwD7ABqE5DYZe9Ci_nZBFKLOUDXmFnt-x4o3apP2vIc2XGyafA9nWE023YauHkPGk0_knWPPVZ9gs-kXyL1BMzy6zeF7dzA0O1xqPAjJsfBM3Ybd6Vy4iXpRxrd28D8B6wFaxbecNfLQNplDH4ad-swOz6dnV6XnSV01ILDp_ljBqLdKElI2JR_-siSDGpRodu8uYoVKUljIjvNeIFEuSOT6mutS55dLllvn8K6xXi8rvQoz02IXgXURVJS29054YqpESaryRyjSC_UF66m-XHEN1aZCJCiJWQcQRnAS5PjUI-azbE4v6j-qHh3LcMGm95SZH_XFujBQ2RFoxYokmJILRoBU12IhCMIh0hyIAieBbp6Cnt4QA_1SmPAKxorqVz1i9Us1v2vTaXGZosuMIDlolv90zdTopAgNl39-ji3vwEcGY7LbKjGB9Wd_7Hwh4luZna86PyK_-kw
  priority: 102
  providerName: Scholars Portal
– databaseName: Wiley-Blackwell Open Access Collection
  dbid: 24P
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT9wwEB4BlRAX1BZoQ2kVIQ5cAoljJ7F6AsQKVVrEASRull-BPTRbJdsD_54ZJxu6gkrcosR5zcPzje35DHDEtKuc5DrJyjJPOMOcVXqDnaHxudOlRhRLM7rT6-Lqjv-6F_dr8HNZC9PzQ4wDbuQZob8mB9emO30hDbX6Nz9B_C_W4QPCmopMmvGbcYAFbZkVIeEixvUE_YgvmYVSdjrevRKPAm3_W1jz9ZLJf6FsiEWTj7A9gMj4rNf6J1jzzWfYnA7T5DswnVxeZ_GseZwZdNgWjwgbdr6LO1qv3m8YEc_ruNVuNpRgPWGr2IaeAx9tyRjamIb1u124m1zeXlwlw74JicXwLxLBrcVEIRUV8xihNSuZcanG0O4yYbgsa8uFKb3XiBVrlrmi4rrWuS2ky63w-R5sNPPGf4UYE2RH5buIq2pee6c9M1xjUqjxRi7TCA6X0lN_enoM1RMhM0UiViTiCM5JrmMDYrQOJ-btgxocRLnCCGm9LUyec8ypjJGlpVorwSzTjEVwsNSKGtysUwgHMeHhCEEi-NIraHwLlfinMi0iKFdUt_IZq1ea2WMg2C5khkZbRXAclPz_P1MXZ1PKQcX--5t-gy0EXbJfEnMAG4v2r_-OwGZhfgQDfgaqzPHL
  priority: 102
  providerName: Wiley-Blackwell
Title FEN1 inhibitor increases sensitivity of radiotherapy in cervical cancer cells
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcam4.2615
https://www.ncbi.nlm.nih.gov/pubmed/31670906
https://www.proquest.com/docview/2326754521/abstract/
https://pubmed.ncbi.nlm.nih.gov/PMC6912068
https://doaj.org/article/d6b59cec6b334666bb97c016552c2a22
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEB7iFEovpe8qTY0oPfQiW1rtarXHxNgNBRlTGvBN7EuNIJaDlB767zO7koJN20svi9BrpZnVzvet5gHwmUiTG0FllHCeRpQgZxVW4WSobGokl4hi3R_dYp1dXdNvW7Y9ATbGwninfa3qWXO7mzX1jfetvNvp-egnNt8Ui0wkeNN8PoEJT9MDiu6nX-6KKiVjFqGYzLXc0RkyBVelxgV-x8LVNzowQz5b_98g5p-ekocI1pug1Qt4PmDH8KJ_xpdwYptX8LQY_o6_hmK1XCdh3dzUCr_TFrccJOxsF3bOTb2vExHuq7CVph4ir37jWaH2EwbeWrsx0IZuNb97A9er5Y_FVTSUS4g0Wn0WMao18oOY5cSiYZaEE2ViiRbdJExRwStNmeLWSoSIFUlMllNZyVRnwqSa2fQtnDb7xr6HEHmxcVG7CKcqWlkjLVFUIheUeCEVcQCfRumVd31WjLLPf0xKJ-3SSTuASyfXxxNcImu_Y9_-LAd1liZTTGirM5WmFKmUUoJrF2LFiCaSkADOR62Uw9fVlYgCkedQRB4BvOsV9NjLqOAA-JHqjh7j-AgOM59XexhWAXzxSv73m5WLi8JRT3b23518gGcIvUTvGHMOp_ftL_sR4c29msKE0A22fMun8ORyud58n_qlAmy_bhNsC5pP_aB_AGtS_xQ
link.rule.ids 230,315,733,786,790,870,891,2115,2236,11589,12083,21416,24346,27957,27958,31754,33779,43345,43840,46087,46511,50849,50958,53827,53829,74102,74659
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB6VRYJeqpZHG0pLhDhwCSSOnaxPFaBdbYGsEAKJm-VXYA_NQgIH_n3HiXfpqsAtSuzEmRl7vhl7ZgD2iDR9w6mMkjxPI0rQZuVW4WKobGpkLhHFuh3dYpyNrunpDbvxDrfGH6ucrYntQm2m2vnID1HzI7alqG1-3T9ErmqU2131JTSWYJmmaKr0YPl4ML64nHtZUKCxWzJLKRSTQy3_0AM0G9iCImrz9b8GMv8_K_kvhm2V0PAzfPLoMTzq2P0FPthqDVYKvz--DsVwME7CSXU3UThTa7xyoLCxTdi4g-pdpYhwWoa1NBMfe_WMrULdLhn4au2koA6dP7_ZgOvh4OpkFPmCCZFGvc8iRrVGCyFmfWJRNUuSE2ViiTrdJExRnpeaMpVbKxEkliQxWZ_KUqY64ybVzKab0Kumlf0GIVrGxsXtIqAqaWmNtERRiSSW2JHyOIDdGfXEfZcXQ3QZkIlwJBaOxAEcO7rOG7hU1u2NaX0r_MwQJlOMa6szlaYUjSmleK5dkBUjmkhCAtiecUX4-dWIF2kI4GvHoPlXXGx_zOMsgHyBdQvDWHxSTe7azNoZT1Ba-wHst0x--8_EyVHhjE-29f7odmB1dFWci_Pf47Pv8BHRFu_OwmxD77F-sj8Q0Tyqn15s_wJ7CvRM
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BkSouiPJMaUuEOHAJmzh2vD6h0nZVHrviQKW9WX6l3QPZkrSH_vvOJN6lK6C3KHEcZ2bs-caeB8B7ZvzYK26yQsoy4wxtVhUsLoY2lN5IgyiWTnSns-r0jH-di3n0f-qiW-VqTewXar90tEc-Qs2P2JajthnV0S3ix_Hk0-XvjCpI0UlrLKfxEB6hlsypmoGcy_V-C4o2dlCskgvlbOTML_4RDQixoZL6zP3_gpt_e03eRbO9Opo8hScRR6aHA-N34EFonsH2NJ6UP4fp5GRWpIvmYmFxzrZ4RfCwC13akcv6UDMiXdZpa_wiRmHdYKvU9YsHdu1IHtqUdva7F3A2Ofl5dJrF0gmZQwQgMsGdQ1shF2MWUEkbJpn1uUHt7gthuZK148LKEAzCxZoVvhpzU5vSVcqXToTyJWw1yya8hhRtZE8RvAital4HbwKz3KBdaPBFrvIE3q2opy-HDBl6yIXMNJFYE4kT-Ex0XTegpNb9jWV7ruMc0b6yQrngKluWHM0qa5V0FG4lmGOGsQT2VlzRcaZ1-o9cJPBqYND6KxTln6u8SkBusG5jGJtPmsVFn2O7UgXK7TiBDz2T__9n-uhwSmao2L1_dG9hG-VVf_8y-_YGHiPsUoNTzB5sXbXXYR-hzZU96GX2Fqga9xI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FEN1+inhibitor+increases+sensitivity+of+radiotherapy+in+cervical+cancer+cells&rft.jtitle=Cancer+medicine+%28Malden%2C+MA%29&rft.au=Jin%E2%80%90Li+Li&rft.au=Jian%E2%80%90Ping+Wang&rft.au=Hong+Chang&rft.au=Sheng%E2%80%90Ming+Deng&rft.date=2019-12-01&rft.pub=Wiley&rft.eissn=2045-7634&rft.volume=8&rft.issue=18&rft.spage=7774&rft.epage=7780&rft_id=info:doi/10.1002%2Fcam4.2615&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_d6b59cec6b334666bb97c016552c2a22
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-7634&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-7634&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-7634&client=summon